TransMedics Group: Positive Trends in Flight and Organ Transplant Volumes Justify Buy Rating
William Blair analyst Ryan Daniels maintains a Buy rating on TransMedics Group (TMDX) due to positive trends in flight and organ transplant volumes, which are recovering from seasonal declines. These metrics are expected to meet or exceed market expectations for Q4. Daniels, a 3-star analyst, has a 2.6% average return and a 41.71% success rate. TD Cowen also maintains a Buy rating with a $170 price target.
William Blair analyst Ryan Daniels has maintained their bullish stance on TMDX stock, giving a Buy rating yesterday.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Ryan Daniels has given his Buy rating due to a combination of factors including the positive trends observed in TransMedics Group’s flight and organ transplant volumes. These metrics have shown a recovery from previous seasonal declines, with flight volumes demonstrating steady momentum as the quarter progresses.
The data indicates that both flight and organ transplant volumes are on track to meet or potentially exceed market expectations for the fourth quarter, provided that December maintains the current pace. This consistent performance supports the outlook for TransMedics Group, justifying the Buy rating assigned by Ryan Daniels.
According to TipRanks, Daniels is a 3-star analyst with an average return of 2.6% and a 41.71% success rate. Daniels covers the Healthcare sector, focusing on stocks such as TransMedics Group, Addus Homecare, and Idexx Laboratories.
In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $170.00 price target.
